Collegium Pharmaceutical Inc (COLL)
33.66
+0.20
(+0.60%)
USD |
NASDAQ |
Nov 04, 12:54
Collegium Pharmaceutical Revenue (Quarterly): 145.28M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 145.28M |
March 31, 2024 | 144.92M |
December 31, 2023 | 149.74M |
September 30, 2023 | 136.71M |
June 30, 2023 | 135.55M |
March 31, 2023 | 144.77M |
December 31, 2022 | 129.62M |
September 30, 2022 | 127.01M |
June 30, 2022 | 123.55M |
March 31, 2022 | 83.75M |
December 31, 2021 | 27.36M |
September 30, 2021 | 78.84M |
June 30, 2021 | 82.94M |
March 31, 2021 | 87.72M |
December 31, 2020 | 76.27M |
September 30, 2020 | 79.18M |
Date | Value |
---|---|
June 30, 2020 | 78.06M |
March 31, 2020 | 76.51M |
December 31, 2019 | 74.20M |
September 30, 2019 | 72.94M |
June 30, 2019 | 75.04M |
March 31, 2019 | 74.52M |
December 31, 2018 | 73.43M |
September 30, 2018 | 70.18M |
June 30, 2018 | 73.06M |
March 31, 2018 | 63.75M |
December 31, 2017 | 10.79M |
September 30, 2017 | 11.95M |
June 30, 2017 | 3.56M |
March 31, 2017 | 2.172M |
December 31, 2016 | 1.303M |
September 30, 2016 | 0.408M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
27.36M
Minimum
Dec 2021
149.74M
Maximum
Dec 2023
104.32M
Average
87.72M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
Rigel Pharmaceuticals Inc | 36.84M |
Esperion Therapeutics Inc | 73.83M |
Context Therapeutics Inc | -- |
NovaBay Pharmaceuticals Inc | 2.40M |
Palatin Technologies Inc | 0.35M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 19.61M |
Total Expenses (Quarterly) | 97.80M |
EPS Diluted (Quarterly) | 0.52 |
Enterprise Value | 1.359B |
Gross Profit Margin (Quarterly) | 62.51% |
Profit Margin (Quarterly) | 13.50% |
Earnings Yield | 7.69% |
Operating Earnings Yield | 13.04% |
Normalized Earnings Yield | 8.051 |